Department of HPB and Digestive Surgery, Ospedale Mauriziano Umberto I, Largo Turati 62, 10129, Turin, Italy.
Int J Colorectal Dis. 2013 Nov;28(11):1523-9. doi: 10.1007/s00384-013-1727-4. Epub 2013 Jul 23.
The lymph node status is one of the strongest prognostic determinants in rectal cancers. After chemoradiotherapy (CRT), lymph nodes are difficult to detect. This study aims to evaluate the feasibility of lymph node mapping in the mesorectum after CRT to analyze the pattern of metastasis spread and to assess the reliability of blue dye injection in sentinel lymph node detection.
Ten patients with cN+ mid/low RCs after CRT were prospectively enrolled. The protocol scheduled intraoperative blue dye injection, surgery, and specimen examination with fat clearance technique. The mesorectum was divided into three equal "levels" (upper, middle, and lower); each level was divided into three equal "sectors" (right anterolateral, posterior, and left anterolateral). Lymph nodes were defined "small" if ≤5 mm.
Two hundred seventy-six lymph nodes were retrieved in ten patients; 76.5 % were small lymph nodes. Six patients were pN+ (33 metastatic lymph nodes, 76 % small); small lymph node analysis upstaged one patient from N0 to N1 and four patients from N1 to N2. Metastasis distribution across sectors was continuous, without "skip sectors." The blue dye detected the sentinel lymph node in all patients; in half of the cases, it was out of the tumor sector. Blue dye identified 69.7 % of metastatic lymph nodes; its sensitivity decreased together with the metastatic deposit size (84 % macrometastases, 28.6 % micrometastases, 0 % occult tumor cells; p = 0.004).
The fat clearance technique should be the standard pathological examination in patients with RCs after CRT; N staging was improved by small lymph node identification. Lymph node metastases have a continuous spread through mesorectal sectors. Blue dye injection is effective in sentinel lymph node detection.
淋巴结状态是直肠癌最强的预后决定因素之一。在放化疗(CRT)后,淋巴结难以检测。本研究旨在评估 CRT 后直肠系膜内淋巴结定位的可行性,分析转移扩散模式,并评估蓝染剂注射在检测前哨淋巴结中的可靠性。
前瞻性纳入 10 例 CRT 后 cN+中低位直肠癌患者。方案安排术中蓝染剂注射、手术和脂肪清除技术下的标本检查。直肠系膜分为三个相等的“水平”(上、中、下);每个水平分为三个相等的“扇区”(右前外侧、后和左前外侧)。淋巴结定义为“小”如果 ≤5mm。
10 例患者共检出 276 个淋巴结;76.5%为小淋巴结。6 例患者为 pN+(33 个转移性淋巴结,76%为小淋巴结);小淋巴结分析将 1 例患者从 N0 分期升级为 N1,4 例患者从 N1 分期升级为 N2。转移灶在扇区之间连续分布,无“跳跃扇区”。蓝染剂在所有患者中均能检测到前哨淋巴结;在一半的情况下,它位于肿瘤扇区之外。蓝染剂识别了 69.7%的转移性淋巴结;其敏感性随转移灶大小而降低(84%大转移灶,28.6%微转移灶,0%隐匿性肿瘤细胞;p=0.004)。
脂肪清除技术应成为 CRT 后直肠癌患者的标准病理检查;通过识别小淋巴结,提高了 N 分期。淋巴结转移通过直肠系膜扇区连续扩散。蓝染剂注射在检测前哨淋巴结中有效。